Skip to main content
    T

    TriSalus Life Sciences Inc. (TLSI)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $2.29
    +0.02 (+1.10%)

    Market Cap: $140.06M

    Last updated: Nov 17, 2026 at 4:26 PM ET

    TriSalus Life Sciences Inc. (TLSI) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    TriSalus Life Sciences (TLSI) has a market cap of $140.06M and an enterprise value of $131.37M. Its share count is up 35.80% from a year earlier. It kept -56.60% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 6.20% below the market cap, as cash exceeds debt.

    Market Cap$140.06M
    Enterprise Value$131.37M
    Latest price (Nov 17, 2026)$2.29

    Key Dates

    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.30% in the quarter ended Sep 30, 2026 and grew 48.54% a year over 2 years.

    Shares Outstanding58.47M
    Shares Change (YoY)+35.80%
    Shares Change (QoQ)+0.30%
    Share Count Growth (2Y CAGR)+48.54%

    Valuation Ratios

    Sales and book value multiples are 2.9x and 198.8x. Its year-end P/S ranged from 0.8x to 5.8x from 2023 to 2025.

    P/S Ratio2.9x
    Forward P/S3.0x
    P/B Ratio198.8x

    Valuation history and multiples

    Price Statistics

    The stock is down 49.67% over 52 weeks and trades 41.88% below its 50-day average.

    Beta (1Y)1.26
    52-Week Change-49.67%
    1-Month Change-34.99%
    3-Month Change-58.20%
    6-Month Change-27.14%
    Total Return (1Y)-49.67%
    Total Return (3Y CAGR)-15.62%
    Return vs SPY (1Y)-61.67%
    Max Drawdown (1Y)-69.73%
    Max Drawdown (3Y)-77.85%
    Sharpe Ratio (1Y)-0.77
    Correlation with SPY (1Y)0.19
    50-Day Average$3.94
    200-Day Average$4.26
    52-Week Range$2.17 to $7.95
    RSI (14 Days)26.9
    Average Volume (20 Days)315.33K

    Price chart

    Financial Position

    Current assets cover 4.22x current liabilities, and total debt is 47.60x shareholder equity.

    Current Ratio4.22x
    Quick Ratio3.86x
    Debt / Equity47.60x
    Interest Coverage-3.62x

    Returns and Efficiency

    Return on invested capital is -65.01% and return on equity is -3861.03% over the last 12 months.

    Return on Equity (ROE)-3861.03%
    Return on Assets (ROA)-45.61%
    Return on Invested Capital (ROIC)-65.01%
    Return on Capital Employed (ROCE)-48.23%
    Asset Turnover0.99x
    Inventory Turnover1.42x
    Receivables Turnover7.37x
    Cash Conversion Cycle74 days

    Scores

    TLSI has an Altman Z-Score of -6.58, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score-6.58
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $46.39M over the last 12 months is up 15.38% from the 12 months before.

    Revenue$46.39M
    Revenue Growth (YoY)+15.38%
    Gross Profit$40.11M
    Operating Income-$29.20M
    Pretax Income-$26.24M
    Net Income-$26.25M
    EBITDA-$19.65M
    EBIT-$21.48M
    Reported EPS (TTM)-$0.33

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 1.18% of the $57.56M in total assets.

    Cash and Equivalents$41.06M
    Total Debt$32.37M
    Net Cash$8.69M
    Net Cash Per Share$0.15
    Working Capital$41.88M
    Shareholder Equity$680.00K
    Book Value Per Share$0.01
    Total Assets$57.56M
    Total Liabilities$56.88M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $354.00K of capital spending, operating cash flow left -$24.72M of free cash flow.

    Operating Cash Flow-$24.37M
    Capital Expenditures$354.00K
    Free Cash Flow-$24.72M
    FCF Per Share-$0.40
    Depreciation and Amortization$1.83M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -62.95%.

    Gross Margin86.46%
    Operating Margin-62.95%
    Pretax Margin-56.57%
    Net Margin-56.60%
    EBITDA Margin-42.36%
    EBIT Margin-46.31%
    FCF Margin-53.29%

    Dividends and Yields

    TLSI does not pay a dividend. Its free cash flow yield is -18.42%.

    FCF Yield-18.42%
    Buyback Yield-32.11%
    Shareholder Yield-32.11%

    Peer Position

    Against 11 similar companies, TLSI has the 4th highest P/S.

    P/S Ratio2.9x vs 1.4x median
    ROIC-65.01% vs -23.33% median
    Revenue Growth (Trailing 4 Quarters, YoY)+15.38% vs +1.60% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 14.76% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+14.76%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About TLSI

    What is TLSI's market cap?

    TriSalus Life Sciences has a market cap of $140.06M. Its enterprise value, which adds debt and subtracts cash, is $131.37M.

    How many shares of TLSI are outstanding?

    TriSalus Life Sciences has 58.47M shares outstanding. The count is up 35.80% from a year earlier.

    Does TLSI pay a dividend?

    No. TriSalus Life Sciences does not pay a dividend.

    How much debt does TLSI have?

    TriSalus Life Sciences has $32.37M of total debt and $41.06M of cash and equivalents, a net cash position of $8.69M.